Evidence map›Paper›PMID 35057796›Full record

ArticleBMC medicine2022

Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.

Justyna Mączyńska, Florian Raes, Chiara Da Pieve, Stephen Turnock, Jessica K R Boult, Julia Hoebart, Marcin Niedbala, Simon P Robinson, Kevin J Harrington, Wojciech Kaspera and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Justyna Mączyńska *Division of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Florian Raes *Division of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Chiara Da PieveDivision of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Stephen TurnockDivision of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Jessica K R BoultDivision of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Julia HoebartDivision of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Marcin NiedbalaDepartment of Neurosurgery, Medical University of Silesia, Regional Hospital, 41-200, Sosnowiec, Poland.
Simon P RobinsonDivision of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Kevin J HarringtonDivision of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
Wojciech KasperaDepartment of Neurosurgery, Medical University of Silesia, Regional Hospital, 41-200, Sosnowiec, Poland. wkaspera@sum.edu.pl.
Gabriela Kramer-MarekDivision of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK. gkramermarek@icr.ac.uk.
Institute of Cancer Research · GBMedical University of Silesia · PL

Funding

Cancer Research UK 27725Cancer Research UK 28724
6 · The paper itself

Abstract

backgroundSurgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative techniques that maximise tumour excision with therapies aiming to remodel the immunologically cold GBM microenvironment could improve patients' outcomes. Herein, we report that targeted photoimmunotherapy (PIT) not only helps to define tumour location and margins but additionally promotes activation of anti-GBM T cell response.

methodsEGFR-specific affibody molecule (Z

resultsIn vitro findings confirmed the ability of Z

conclusionsOur data underline the potential of Z

Indexed as

GlioblastomaAnimalsAutoantibodiesCell Line, TumorErbB ReceptorsHumansImmunityImmunotherapyMiceNeoplasm Recurrence, LocalPhotosensitizing AgentsTumor MicroenvironmentXenograft Model Antitumor Assaysantiglomerular basement membrane antibodyAutoantibodiesEGFR protein, humanErbB ReceptorsPhotosensitizing AgentsAffibody moleculesGlioblastomaIR700Photoimmunotherapy

Identifiers

PMID35057796
PMCPMC8780306
OpenAlexW4225248620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.